Advancing Knowledge. Enhancing Care.
Advancing Knowledge. Enhancing Care.

Psoriasis Review newsletter

Subscribe

To receive the newest issue in your inbox

Psoriasis News

3/31/2020 10:15:00 AM
Lilly's TALTZ® (IXEKIZUMAB) receives U.S. FDA approval for the treatment of pediatric patients with moderate to severe plaque psoriasis
3/11/2020 1:09:00 PM
For psoriasis patients diagnosed with COVID-19 disease, the IPC recommends physicians discontinue or postpone use of immunosuppressant medications. This is in accordance with established psoriasis treatment guidelines, which state immunosuppressive psoriasis treatments are contraindicated in patients with active infections.
2/6/2020 10:54:00 AM
Just published - IPC's latest issue of the Psoriasis Review newsletter is now available! This issue features the Top Five Papers in psoriasis research, symposia reports, IPC news, and more!
2/6/2020
More News


We use cookies on this website to enhance your experience. By continuing with this website, you consent to our use of cookies. Learn more.
OK